March 11, 2020 PR-M03-20-NI-016
NEWARK, NJ – The New Jersey Innovation Institute’s (NJII) Biopharma division is pleased to announce the formation of their advisory committee which includes experts from across the industry.
The committee will meet quarterly and provide strategic direction to the division as well as help identify emerging opportunities and challenges in the area of regenerative medicine.
“This group of recognized experts will provide insights and strategic advice to help us develop capabilities and tools to support the biopharma industry’s ability to adapt to new technologies and innovations in cell and gene therapy,” said NJII Senior Vice President for Biopharma, Dr. Haro Hartounian. “I’ve known many of the committee members for years, but getting them all together, on our team, is a great honor.”
The chairwoman of the committee will be Dr. Joanne Beck, chief operating officer of Boston Pharmaceuticals. “NJII has made significant progress in the area of regenerative medicine and we are very excited for the launch of their new center and the opportunity for companies of varying sizes to leverage the center for cell and gene therapy development and manufacturing projects as well as workforce development.” Beck stated.
Members of the committee include:
The Biopharma division that Dr. Hartounian leads provides both well-established bio-pharmaceutical companies and promising start-ups access to a more affordable, efficient and flexible option for product development as well as workforce development programs that focus on the latest advances and technologies for cell and gene therapy development and manufacturing.
NJII, a New Jersey Institute of Technology corporation, is set to open the multi-million dollar Cell and Gene Therapy Development Center on the university’s Newark, NJ campus this May. The facility will be the first center of its kind in Newark, NJ and the only center of its kind on a University campus here in the United States.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
The New Jersey Innovation Institute (NJII) is an NJIT corporation that applies the intellectual and technological resources of New Jersey’s public polytechnic university to challenges identified by industry partners in key economic sectors. NJII currently manages solutions and programs for Biopharma, Data & Technology, Defense, Entrepreneurship. Healthcare and Human Capital.